FDA cancels meeting on J&J’s ceftobiprole
Executive Summary
FDA cancels the Anti-Infective Drugs Advisory Committee meeting scheduled for Feb. 28 to discuss Johnson & Johnson's NDA for the broad-spectrum cephalosporin antibiotic ceftobiprole. The committee will still meet on Feb. 27 to discuss Theravance's telavancin for the treatment of complicated skin and skin structure infection (1"The Pink Sheet," Jan. 14, 2008, In Brief)...